Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lisa Takagi

Managing Editor

Tokyo, Japan

Lisa provides editorial coverage of all aspects of Japan’s prescription drug market for Scrip and Pink Sheet, including company, market, pricing and regulatory developments, as well as publishing podcast content regularly in the local Japanese language.

Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she covered the IT sector for ITmedia Enterprise in Japan. Lisa is bilingual in Japanese and English. She speaks basic French and Mandarin with keen interests in learning new languages. She holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada.

Latest From Lisa Takagi

Japan Academia Progresses Novel Melanoma Drug Despite Pharma 'Reluctance'

Academia-developed novel oral PAI-1 inhibitor in combination with Opdivo showed a strong response rate in PD-1 treated melanoma patients with certain disease characteristics and could represent a new breakthrough for a class with no clinical stage competitors. 

Japan Rare Diseases

Asia Deal Watch: Chugai Extends Relationship With Helsinn

Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.

Deal Watch Business Strategies

US R&D Setbacks For Multiple Japanese Firms

Several Japanese firms are facing R&D challenges and setbacks in the US, in the form of missed Phase III endpoints, trial recruitment difficulties and a Complete Response Letter.

Research & Development Clinical Trials

Shionogi, Qpex Agree On Anti-Infective-Focused US R&D Site

Shionogi says first major US R&D site will enhance capabilities for both Shionogi and its 2023 acquisition Qpex, which prompted the Japanese firm to build on the San Diego company's close research collaborations with US government organizations.

Research & Development Strategy

Japan Nods Include Torii's Vtama, Skyrizi In New Uses

Japan issues approval recommendations in new indications, including Torii's Vtama in atopic dermatitis and AbbVie's Skyrizi in ulcerative colitis. Separately, filing requirements for the use of concomitant therapies have been revised.

Japan Drug Review

Japan Aims To Broaden RWD Use By Allowing Pseudonymised Data

Japan has been promoting a revised law that will allow the broader use of real world data by allowing the use of both pseudonymised and anonymised data.

Japan Real-World Evidence
See All